These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9355172)

  • 1. Methods of cost-effectiveness analysis in the assessment of new drugs for Alzheimer's disease.
    Neumann PJ; Hermann RC; Berenbaum PA; Weinstein MC
    Psychiatr Serv; 1997 Nov; 48(11):1440-4. PubMed ID: 9355172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
    Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
    Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society.
    Small GW; Rabins PV; Barry PP; Buckholtz NS; DeKosky ST; Ferris SH; Finkel SI; Gwyther LP; Khachaturian ZS; Lebowitz BD; McRae TD; Morris JC; Oakley F; Schneider LS; Streim JE; Sunderland T; Teri LA; Tune LE
    JAMA; 1997 Oct 22-29; 278(16):1363-71. PubMed ID: 9343469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
    Jönsson L
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of care in a mild-to-moderate Alzheimer clinical trial sample: key resources and their determinants.
    Gustavsson A; Cattelin F; Jönsson L
    Alzheimers Dement; 2011 Jul; 7(4):466-73. PubMed ID: 21784355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost of Alzheimer's disease in managed care: a cross-sectional study.
    Leon J; Neumann PJ
    Am J Manag Care; 1999 Jul; 5(7):867-77. PubMed ID: 10557408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council.
    Fillit H; Cummings J
    Manag Care Interface; 2000 Jan; 13(1):51-6. PubMed ID: 10747691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic considerations in Alzheimer's disease.
    Meek PD; McKeithan K; Schumock GT
    Pharmacotherapy; 1998; 18(2 Pt 2):68-73; discussion 79-82. PubMed ID: 9543467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic effect of cholinesterase inhibitor therapy: implications for managed care.
    Sano M
    Manag Care Interface; 2004 Aug; 17(8):44-9. PubMed ID: 15471110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
    López-Bastida J; Hart W; García-Pérez L; Linertová R
    J Alzheimers Dis; 2009; 16(2):399-407. PubMed ID: 19221429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacoeconomics of Alzheimer's disease.
    Fillit HM
    Am J Manag Care; 2000 Dec; 6(22 Suppl):S1139-44; discussion S1145-8. PubMed ID: 11142178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pursuing cost-effectiveness in mental health service delivery for youth with complex needs.
    Grimes KE; Schulz MF; Cohen SA; Mullin BO; Lehar SE; Tien S
    J Ment Health Policy Econ; 2011 Jun; 14(2):73-83. PubMed ID: 21881163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria.
    Wimo A; Ballard C; Brayne C; Gauthier S; Handels R; Jones RW; Jonsson L; Khachaturian AS; Kramberger M
    J Intern Med; 2014 Mar; 275(3):304-16. PubMed ID: 24605810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.
    Antonanzas F; Rive B; Badenas JM; Gomez-Lus S; Guilhaume C
    Eur J Health Econ; 2006 Jun; 7(2):137-44. PubMed ID: 16670912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective.
    Rice DP; Fillit HM; Max W; Knopman DS; Lloyd JR; Duttagupta S
    Am J Manag Care; 2001 Aug; 7(8):809-18. PubMed ID: 11519239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early identification and treatment of Alzheimer's disease: social and fiscal outcomes.
    Weimer DL; Sager MA
    Alzheimers Dement; 2009 May; 5(3):215-26. PubMed ID: 19362885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential cost-effectiveness of a family-based program in mild Alzheimer's disease patients.
    Martikainen J; Valtonen H; Pirttilä T
    Eur J Health Econ; 2004 Jun; 5(2):136-42. PubMed ID: 15452750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economics of Alzheimer disease.
    Leung GM; Yeung RY; Chi I; Chu LW
    Dement Geriatr Cogn Disord; 2003; 15(1):34-43. PubMed ID: 12457077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.